Inventor · disambiguated record
Jonathan A. Pachter
Also filed as: PACHTER JONATHAN A
22 granted patents·24 pending applications·194 citations·filing 1994–2023
95Inventor score
Top patents by PatentIndex Score
46 records- 0196US7217796B2Neutralizing human anti-IGFR antibodySCHERING CORP·Filed 2003·Granted May 15, 2007·105 cites·81 claims
- 0291US10532056B2Therapeutic compositions, combinations, and methods of useVERASTEM INC·Filed 2016·Granted Jan 14, 2020·6 cites·27 claims
- 0387US7851181B2Neutralizing human anti-IGFR antibodySCHERING CORP·Filed 2007·Granted Dec 14, 2010·7 cites·45 claims
- 0487US7847068B2Neutralizing human anti-IGFR antibodySCHERING CORP·Filed 2006·Granted Dec 7, 2010·7 cites·99 claims
- 0586US7667021B2Neutralizing human anti-IGFR antibodySCHERING CORP·Filed 2006·Granted Feb 23, 2010·6 cites·46 claims
- 0686US6710037B2Method of treating androgen-dependent disordersSCHERING CORP·Filed 2002·Granted Mar 23, 2004·23 cites·13 claims
- 0785US10406158B2Methods and compositions for treating abnormal cell growthVERASTEM INC·Filed 2018·Granted Sep 10, 2019·5 cites·11 claims
- 0885US9962385B2Methods and compositions for treating abnormal cell growthVERASTEM INC·Filed 2015·Granted May 8, 2018·6 cites·16 claims
- 0984US7998688B2Inhibition of EMT induction in tumor cells by anti-cancer agentsOSI PHARMACEUTICALS LLC·Filed 2009·Granted Aug 16, 2011·5 cites·13 claims
- 1083US7811562B2Biomarkers for pre-selection of patients for anti-IGF1R therapySCHERING CORP·Filed 2005·Granted Oct 12, 2010·7 cites·16 claims
- 1182US11564927B2Therapeutic compositions, combinations, and methods of useVERASTEM INC·Filed 2019·Granted Jan 31, 2023·1 cites·18 claims
- 1280US7138396B217 β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseasesSCHERING CORP·Filed 2005·Granted Nov 21, 2006·3 cites·12 claims
- 1377US8173779B2Neutralizing human anti-IGFR antibodyWANG YAN·Filed 2010·Granted May 8, 2012·2 cites·16 claims
- 1475US2023321097A1Methods and compositions for treating abnormal cell growthVERASTEM INC·Filed 2022·Application pending·0 cites
- 1574US7485645B217β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseasesSCHERING CORP·Filed 2007·Granted Feb 3, 2009·1 cites·2 claims
- 1674US7432268B217β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseasesSCHERING CORP·Filed 2005·Granted Oct 7, 2008·1 cites·16 claims
- 1774US7271175B217β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseasesSCHERING CORP·Filed 2006·Granted Sep 18, 2007·1 cites·9 claims
- 1873US2024000790A1Therapeutic compositions, combinations, and methods of useVERASTEM INC·Filed 2022·Application pending·0 cites
- 1969US6903102B217β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseasesSCHERING CORP·Filed 2002·Granted Jun 7, 2005·3 cites·29 claims
- 2065US7790474B1p53 modulatorsSCHERING CORP·Filed 2006·Granted Sep 7, 2010·2 cites·10 claims
- 2165US2025367201A1Combination therapy for treating abnormal cell growthVERASTEM INC·Filed 2023·Application pending·0 cites
- 2262US8017735B2Anti-IGFR1 antibody therapeutic combinationsSCHERING CORP·Filed 2004·Granted Sep 13, 2011·1 cites·41 claims
- 2361US2024382485A1Methods of treating abnormal cell growthVERASTEM INC·Filed 2022·Application pending·0 cites
- 2460US2025049792A1Combination therapy for treating abnormal cell growthVERASTEM INC·Filed 2022·Application pending·0 cites
- 2559US2020147080A1Methods and compositions for treating abnormal cell growthVERASTEM INC·Filed 2019·Application pending·0 cites
- 2658US2025064804A1Combination therapy for treating abnormal cell growthVERASTEM INC·Filed 2022·Application pending·0 cites
- 2757US2023330088A1Combination therapy for treating abnormal cell growthVERASTEM INC·Filed 2021·Application pending·0 cites
- 2857US2015093398A1Methods and Compositions for Treating or Preventing CancerMERCK SHARP & DOHME·Filed 2014·Application pending·0 cites
- 2956US7053091B217 β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseasesSCHERING CORP·Filed 2003·Granted May 30, 2006·0 cites·22 claims
- 3055US2023103007A1Combination therapy for treating abnormal cell growthVERASTEM INC·Filed 2021·Application pending·0 cites
- 3155US2025099467A1Combination therapy for treating abnormal cell growthVERASTEM INC·Filed 2023·Application pending·0 cites
- 3254US2022387491A1Methods of making cellular therapiesSECURA BIO INC·Filed 2020·Application pending·0 cites
- 3354US2025009746A1Combination therapy for treating abnormal cell growthVERASTEM INC·Filed 2022·Application pending·0 cites
- 3451US6569872B1Use of neurokinin receptor antagonists to treat androgen-dependent diseasesSCHERING CORP·Filed 2002·Granted May 27, 2003·1 cites·30 claims
- 3551US2006233810A1Methods and compositions for treating or preventing cancerWANG YAOLIN·Filed 2006·Application pending·0 cites
- 3651US2024115571A1Combination therapy for treating abnormal cell growthVERASTEM INC·Filed 2022·Application pending·0 cites
- 3750US2021338681A1Combination therapiesSECURA BIO INC·Filed 2019·Application pending·0 cites
- 3848US2011014117A1Anti-igf1rSCHERING CORP·Filed 2008·Application pending·0 cites
- 3946US2023201198A1Methods of treating abnormal cell growthVERASTEM INC·Filed 2021·Application pending·0 cites
- 4046US2004235908A13,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonistsSCHERING CORP·Filed 2004·Application pending·0 cites
- 4144US2003204085A13, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonistsFiled 2002·Application pending·0 cites
- 4240US2015071947A1Methods of identifying gene isoforms for anti-cancer treatmentsVERASTEM INC·Filed 2013·Application pending·0 cites
- 4340US2015030615A1Biomarkers for cancer stem cells and related methods of useVERASTEM INC·Filed 2013·Application pending·0 cites
- 4439US5461057AHydro-ethano-indeno-pyridinesSCHERING CORP·Filed 1994·Granted Oct 24, 1995·1 cites·17 claims
- 4539US2003097004A13,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonistsSCHERING CORP·Filed 2002·Application pending·0 cites
- 4632US2012189641A1Combination anti-cancer therapyBUCK ELIZABETH A·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jonathan A. Pachter files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →